{"organizations": [], "uuid": "93286f866651262372cd4030610a4d03bb8ea47d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-arca-biopharma-anticipates-meeting/brief-arca-biopharma-anticipates-meeting-with-fda-in-q2-idUSASB0C7ED", "country": "US", "domain_rank": 408, "title": "BRIEF-ARCA Biopharma Anticipates Meeting With FDA In Q2", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-26T15:29:00.000+02:00", "replies_count": 0, "uuid": "93286f866651262372cd4030610a4d03bb8ea47d"}, "author": "", "url": "https://www.reuters.com/article/brief-arca-biopharma-anticipates-meeting/brief-arca-biopharma-anticipates-meeting-with-fda-in-q2-idUSASB0C7ED", "ord_in_thread": 0, "title": "BRIEF-ARCA Biopharma Anticipates Meeting With FDA In Q2", "locations": [], "entities": {"persons": [{"name": "gencaro", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "arca biopharma inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 32 PM / Updated 7 minutes ago BRIEF-ARCA Biopharma Anticipates Meeting With FDA In Q2 Reuters Staff Feb 26 (Reuters) - ARCA Biopharma Inc: * ARCA BIOPHARMA REPORTS TOPLINE PHASE 2B RESULTS FOR GENETIC-AF CLINICAL TRIAL * ARCA BIOPHARMA INC - ‍ANTICIPATES MEETING WITH U.S. FDA IN Q2 OF 2018 TO REVIEW PHASE 2 DATA AND PHASE 3 DEVELOPMENT PLAN​ * ARCA BIOPHARMA INC - ‍GENCARO DEMONSTRATES COMPARABLE EFFICACY TO ACTIVE CONTROL AND TREND FOR POTENTIAL GENCARO SUPERIORITY IN US PATIENT COHORT​ * ARCA BIOPHARMA INC - ‍SAFETY DATA INDICATED THAT GENCARO WAS GENERALLY SAFE AND WELL-TOLERATED IN AF/HEART FAILURE POPULATION​ * ARCA BIOPHARMA INC - ‍THREE PATIENTS DIED IN LONG-TERM TREATMENT EXTENSION PERIOD AFTER RECEIVING GENCARO FOR MORE THAN A YEAR​ * ARCA BIOPHARMA INC - ‍ENDED 2017 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $11.8 MILLION​ * ARCA BIOPHARMA - ‍BELIEVES FUNDS, WITH NET PROCEEDS OF ABOUT $3.4 MILLION RAISED IN JAN WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2018​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-26T15:29:00.000+02:00", "crawled": "2018-02-26T15:50:56.053+02:00", "highlightTitle": ""}